MX2019002627A - Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo. - Google Patents

Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo.

Info

Publication number
MX2019002627A
MX2019002627A MX2019002627A MX2019002627A MX2019002627A MX 2019002627 A MX2019002627 A MX 2019002627A MX 2019002627 A MX2019002627 A MX 2019002627A MX 2019002627 A MX2019002627 A MX 2019002627A MX 2019002627 A MX2019002627 A MX 2019002627A
Authority
MX
Mexico
Prior art keywords
methods
azetidin
triazolo
compositions
pyridinyl compounds
Prior art date
Application number
MX2019002627A
Other languages
English (en)
Inventor
Zak Mark
Xing Cheng Yun-
Charles Goodacre Simon
Anthony Romero F
Cheng Limin
Hua Rongbao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019002627A publication Critical patent/MX2019002627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de fórmulas (I) y (II), o un estereoisómero, tautómero, solvato, profármaco o sal del mismo, y métodos de uso como inhibidores de cinasas de Janus.
MX2019002627A 2016-09-06 2017-09-02 Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo. MX2019002627A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016098215 2016-09-06
PCT/EP2017/072034 WO2018046409A1 (en) 2016-09-06 2017-09-02 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019002627A true MX2019002627A (es) 2019-10-30

Family

ID=59761965

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002627A MX2019002627A (es) 2016-09-06 2017-09-02 Compuestos de 8-(azetidin-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de uso del mismo.

Country Status (19)

Country Link
US (3) US20190202822A1 (es)
EP (2) EP4198036A1 (es)
JP (1) JP7050761B2 (es)
KR (1) KR20190045302A (es)
CN (1) CN109890817B (es)
AU (1) AU2017324281A1 (es)
BR (1) BR112019004486A2 (es)
CA (1) CA3035712A1 (es)
CL (1) CL2019000568A1 (es)
CO (1) CO2019002171A2 (es)
CR (1) CR20190118A (es)
IL (1) IL265153A (es)
MA (1) MA46176A (es)
MX (1) MX2019002627A (es)
PE (1) PE20190632A1 (es)
PH (1) PH12019500478A1 (es)
RU (1) RU2019109570A (es)
SG (1) SG11201901954XA (es)
WO (1) WO2018046409A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022537354A (ja) * 2019-06-18 2022-08-25 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024148184A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Compounds and processes for the preparation of jak inhibitors
WO2024148186A1 (en) * 2023-01-04 2024-07-11 Aerie Pharmaceuticals, Inc. Polymorphs of a jak1/tyk2 inhibitor and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
WO2003053930A1 (en) 2001-12-20 2003-07-03 Bayer Healthcare Ag 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
MX2010014005A (es) 2008-06-20 2011-02-15 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010141796A2 (en) 2009-06-05 2010-12-09 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
TWI719401B (zh) * 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
MX2016002764A (es) * 2013-09-05 2016-05-26 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos.
JP2018507236A (ja) * 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法

Also Published As

Publication number Publication date
SG11201901954XA (en) 2019-04-29
CN109890817A (zh) 2019-06-14
EP3510030A1 (en) 2019-07-17
PH12019500478A1 (en) 2019-12-02
PE20190632A1 (es) 2019-04-26
CO2019002171A2 (es) 2019-05-21
EP3510030B1 (en) 2023-03-22
CR20190118A (es) 2019-04-30
US20200270248A1 (en) 2020-08-27
AU2017324281A1 (en) 2019-03-21
IL265153A (en) 2019-05-30
RU2019109570A (ru) 2020-10-08
JP2019526593A (ja) 2019-09-19
WO2018046409A1 (en) 2018-03-15
MA46176A (fr) 2019-07-17
US20230242530A1 (en) 2023-08-03
RU2019109570A3 (es) 2020-10-08
CA3035712A1 (en) 2018-03-15
KR20190045302A (ko) 2019-05-02
CN109890817B (zh) 2022-06-17
EP4198036A1 (en) 2023-06-21
US20190202822A1 (en) 2019-07-04
CL2019000568A1 (es) 2019-07-12
BR112019004486A2 (pt) 2019-05-28
JP7050761B2 (ja) 2022-04-08

Similar Documents

Publication Publication Date Title
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
IL277576A (en) Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
PH12018500792A1 (en) Benzolactam compounds as protein kinase inhibitors
IL265918B (en) Converted pyrazolo[1,5–a]pyridine compounds as ret kinase inhibitors
PH12019500478A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
MX2020003458A (es) Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[ 5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3- carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo.
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2018013191A (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
SI3880676T1 (sl) Derivati 2,3-dihidro-1h-pirolo(3,4-c)piridin-1-ona kot zaviralci hpk1 za zdravljenje raka
EP3877371A4 (en) IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES USED AS JANUS KINASE 2 INHIBITORS AND ASSOCIATED USES
WO2018218197A3 (en) ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE
IL288529A (en) History of imidazo[2,1-c]pyrimidine as prc2 inhibitors for cancer therapy
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER